Business Wire

IL-PRICEFX

Share
Pricefx Partners with Bain & Company to Launch the Pricing Industry’s First Big Data Powered Benchmarking Platform

Pricefx , the global leader in cloud-native pricing software, today launched PricefxPlasma™, the first big data powered benchmarking platform for the pricing industry. Powered by Bain & Company , PricefxPlasma leverages real world pricing data mapped to industry standard key performance indicators (KPIs). Businesses can discover strategic insights on their own pricing processes and performance as compared to market averages using benchmarks on a pre-defined set of industry relevant KPIs.

“Every company is looking for an edge over the competition and pricing is one of the strongest levers for success in the marketplace,” said Marcin Cichon, CEO and co-founder at Pricefx. “By launching the first pricing analytics and intelligence platform via a joint project with our valued partners at Bain, Pricefx is giving its customers a whole new level of cross-industry insights. PricefxPlasma is a revolutionary new offering for the pricing industry, providing businesses the information and insights to improve pricing efficiency and effectiveness and uncover new opportunities for revenue growth.”

PricefxPlasma combines a massive amount of anonymized and aggregated transaction and quoting data from industries, sliced and segmented by region, industry and other factors. Data is then compiled into more than 20 pricing performance benchmarks, delivered in intuitive visual outputs and designed to answer the most important pricing analytics questions.

KPIs currently measured in PricefxPlasma include:

  • End-to-end price waterfall: detailed price buildup, including on- and off-invoice discounts, cost elements, geographical prices, list prices and margin elements.
  • Deal approval process: deal velocity, the percent of deals outside discount guidelines, the number of steps in the approval process.
  • Price setting: the value capture of price increases, the number of list price changes per year.
  • Measures of customer and product concentration: the percent of customers/products to reach revenue deciles.

Companies often struggle to understand how their pricing practices measure up to industry best practices. Additionally, according to a Bain & Company survey , many B2B companies do not provide their salesforce with the right tools and data to make effective pricing decisions.

“Companies typically assess the effectiveness of their pricing strategy and execution using a combination of anecdotal data, generic or poorly defined benchmarks, and a lot of guesswork,” said Robert Kugel, Senior Vice President and Research Director at Ventana Research. “Having reliable industry benchmarks derived from real world data provides businesses valuable insight to how they measure up to their peers. PricefxPlasma is an attempt to make useful benchmarks readily available and consumable. Having reliable pricing data also can help businesses identify market trends that enable them to make better decisions about strategy, investments and products.”

How PricefxPlasma Works

Pricefx gathers, anonymizes and aggregates its customers’ data into standardized metrics. These metrics are loaded into the PricefxPlasma platform, which aggregates and filters the metrics further to create industry-level benchmarks. The customer's data is anonymized by Pricefx via double-blinding, ensuring that it is impossible to trace individual customer data.

Industry benchmarks are compiled from aggregated metrics from a number of anonymized entities. The resulting benchmarks are distributed to Pricefx’s customers’ environment. Customers can view these benchmarks through a set of standard Pricefx dashboards and customers can also include this data in their own dashboards, allowing for a direct comparison between their company and the benchmark. Benchmarks may be filtered by industry and region to arrive at the desired peer set.

Pricefx partnered with Bain & Company, a global management consulting firm, to develop the benchmarking capabilities and IT systems.

“Combining Pricefx’s world-class pricing software with best practices from Bain’s Pricing and Benchmarking Centers of Excellence, PricefxPlasma provides unique pricing insights never before available that compare your pricing processes and performance to peers,” said Ron Kermisch, Partner at Bain & Company. “Together, we discovered a way to aggregate massive amounts of valuable data and synthesize that data into market relevant KPIs for B2B enterprises to unlock data-driven insights and create a business advantage.”

Pricefx and Bain & Company previously collaborated to launch price Accelerators and the Bain Pricing Navigator powered by Pricefx. Pricefx is a member of the Bain Alliance Ecosystem – a network of best-of-breed partnerships with complementary tool, technology and service providers that accelerates delivery of breakthrough client results.

Availability

PricefxPlasma is available now and is free of charge to Pricefx customers. More information can be found at www.pricefx.com/pricefxplasma . Insights from the platform will also be available to Bain clients and more information can be found at www.bain.com/pricefxplasma .

About Bain & Company

Bain & Company is a global consultancy that helps the world’s most ambitious change makers define the future. Across 59 offices in 37 countries, we work alongside our clients as one team with a shared ambition to achieve extraordinary results, outperform the competition and redefine industries. We complement our tailored, integrated expertise with a vibrant ecosystem of digital innovators to deliver better, faster and more enduring outcomes. Our 10-year commitment to invest more than $1 billion in pro bono services brings our talent, expertise and insight to organizations tackling today’s urgent challenges in education, racial equity, social justice, economic development and the environment. Since our founding in 1973, we have measured our success by the success of our clients, and we proudly maintain the highest level of client advocacy in the industry.

Learn more at www.bain.com and follow us on Twitter @BainAlerts.

About Pricefx

Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Its innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com .

PricefxPlasma™ is a trademark of Price f(x) AG.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye